Abstract |
Serum TBII measured by radioreceptor assay using 125I-
bovine TSH and porcine thyroid well membrane was
checked before, 6 months and 12 months after initiation
of thionamide regimens in 63 Graves' disease patients
and was related with their remission state. 1) A
significant difference (p〈0.01) in pretreatment TBII
was noted between the remitted [N=45, TBII 40.9±18.2%
(mean±S.D)] and the unremitted (N=18, TBII
64.1±15.3%) groups. 2) After 6 months of therapy, TBII
were significantly decreased in both groups (to
20.2±10.3% and to 45.2±16.3%, p〈0.05 for each
group). 3) At 12th month, TBII activities were not
significantly decreased compared to the 6th month
levels in both groups. 4) 3 of the 58 patients who were
initially TBII positive (over 15%) converted negative.
All the 3 belonged to the remitted group. 5) No
significant differences were seen in initial and
posttreatment TBII levels between propylthiouracil
treated (N=36) and methimazole treated (N=27) cases.
with above mentioned results, we observed that the TBII
decreased significantly with 6 months of thionamide
therapy and concluded that the pretreatment measurement
of serum TBII may be clinically useful in predicting
the response to thionamide regimen in the treatment of
Graves' disease. |